Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

NCT05304377 is registered in ClinicalTrials.gov with Enliven Therapeutics as lead sponsor.

NCT NCT05304377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
Lead sponsor
Enliven Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
May 22, 2022
Completion date
December 31, 2027
Enrollment
250 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic phase chronic myeloid leukemia, bcr-abl1 positive, cml